Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p277 | Nutrition | ECTS2016

Association between the sideways fall fractures and body mass index in patients from a public Mexican hospital

Pacheco-Pantoja Elda , Garcia-Ojeda Marycruz , Ramos-Pereyra Viridiana , Sanchez-de-la-Cruz Cindy , Diaz-Diaz Cristel , Osorio-Merito Nallely

The body mass index has been regarded as a risk predictor factor for fractures, and in some prospective cohort studies it has been suggested that obesity could be a protective factor for hip fractures in adults.The present study aimed to investigate whether body mass index is related to the fracture risk when individuals had sideways falls in Mexican patients. We analyzed files from 448 patients, which checked in at Orthopedics and Traumatology Service i...

ba0005p462 | Other diseases of bone and mineral metabolism | ECTS2016

Secondary bone size deficit in patients with Ehlers–Danlos syndrome

Verroken Charlotte , Calders Patrick , Wandele Inge De , Malfait Fransiska , Zmierczak Hans , Goemaere Stefan , Kaufman Jean-Marc , Lapauw Bruno , Rombaut Lies

Background: Ehlers–Danlos syndrome (EDS) comprises a group of inherited connective tissue disorders, caused by various defects in the biosynthesis or secretion of fibrillar collagens. As collagen represents a major constituent of the bone matrix as well as of tendons and muscle, bone strength in EDS patients might be impaired both via direct and indirect pathways. Although decreased muscle strength, decreased areal bone mineral density (BMD) and increased fracture risk ha...

ba0006p034 | (1) | ICCBH2017

Identification of bone remodelling alterations in Gorham-Stout disease

Rossi Michela , Battafarano Giulia , Buonuomo Paola Sabrina , Jenkner Alessandro , Rana Ippolita , De Vito Rita , Bartuli Andrea , Del Fattore Andrea

Objectives: Gorham-Stout disease (GSD) is a very rare disorder characterized by extensive angiomatous proliferation and progressive osteolysis without new bone formation. Only ~200 patients were reported. The quality of life is very poor since patients display pain, fractures, functional impairment and swelling of the affected regions. The ethiology of GSD is unknown. We aim to investigate the bone phenotype and to identify molecular and cellular defects in GSD patients.<p...

ba0006p119 | (1) | ICCBH2017

Phenotypic spectrum in Weyers acrofacial dysostosis: A case report

Rubino Chiara , Stagi Stefano , Petrolini Chiara , Gioe Daniela , La Spina Luisa , Peluso Francesca , Della Monica Matteo , de Martino Maurizio

Background: Weyers acrofacial dysostosis (WAD, OMIM 193530) is a rare autosomal dominant disease, characterized by mildly short stature, postaxial polydactyly, nail dystrophy and dental anomalies. WAD should be distinguished from Ellis-van Creveld syndrome (OMIM 225500), a similar but more severe disease, comprising chondrodysplasia, orofacial anomalies and, in a proportion of patients, cardiovascular malformations. Both diseases are caused by mutations in either EVC or EVC2<s...

ba0007p118 | (1) | ICCBH2019

Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome

Caffarelli Carla , Dea Tomai Pitinca Maria , Francolini Valentina , Canitano Roberto , De felice Claudio , Hayek Joussef , Gonnelli Stefano

Objective: Rett syndrome (RTT) is an X-linked neurodevelopment disorder. More than 95% of RTT female have mutations in methyl-CpG-binding protein 2 (MECP2), whose protein product modulates gene transcription. Specific MECP2 mutations may lead phenotypic variability and different degrees of disease severity. It is known that low bone mass is a frequent complication of subjects with Rett syndrome. This study aimed to investigate if specific MECP2 mutations may affects the degree...

ba0001oc1.6 | Osteoporosis epidemiology and long term treatment complications | ECTS2013

Femur geometrical parameters in the pathogenesis of atypical femur fractures

Morin Suzanne N , Godbout Benoit , Wall Michelle , Belzile Etienne L , Michou Laetitia , Ste-Marie Louis-Georges , Karaplis Andrew C , de Guise Jacques A , Brown Jacques P

Background: Atypical femur fractures (AFF) arise in the subtrochanteric and diaphyseal regions. Because of this unique distribution, we hypothesized that patients with AFF demonstrate specific geometrical variations of their femur whereby baseline tensile forces applied to the lateral cortex are higher and might favor the appearance of these rare stress fractures, when exposed to bisphosphonates.Methods: Subjects who sustained AFF, as defined by the ASBM...

ba0001pp178 | Cell biology: osteoblasts and bone formation | ECTS2013

Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue

Deschaseaux Frederic , Gaillard Julien , Langonne Alain , Chauveau Christophe , Naji Abderrahim , Bouacida Amina , Rosset Philippe , Heymann Dominique , de Pinieux Gonzague , Rouas-Freiss Nathalie , Sensebe Luc

Bone-marrow mesenchymal stem cells (MSCs) are the origin of bone-forming cells with immunomodulation potential. Among the generated immunosuppressive molecules there is HLA-G5. HLA-G proteins play a crucial role in promoting the acceptance of allografts. However, the mechanisms regulating the expression of HLA-G5 in human MSCs are unknown. We induced differentiation of human MSCs (harvested from iliac crests of healthy volunteers after their informed consent following approved...

ba0001pp448 | Osteoporosis: treatment | ECTS2013

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Benhamou Claude , De Villiers Tobias , Johnston C Conrad , Langdahl Bente , Saag Kenneth , Denker Andrew , Pong Annpey , McGinnis John P , Rosenberg Elizabeth , Santora Arthur

Relatively little is known about immediate consequences of continuing vs interrupting long-term bisphosphonate treatment. This report describes changes in bone turnover and BMD in a 1-year, dose-finding trial of the calcium-sensing receptor antagonist MK-5442 in postmenopausal, BP-treated women, randomized to continued alendronate 70 mg weekly, switch to placebo, or switch to MK-5442. Recruited women (n=526) had taken alendronate for ≥12 months and an oral BP fo...